|
KMID : 0358319960370050585
|
|
Korean Journal of Urology
1996 Volume.37 No. 5 p.585 ~ p.589
|
|
|
Prostaglandin E1 Monotherapy for Impotence
|
|
|
|
|
Abstract
|
|
|
Intracavernous injection of prostaglandin E1 as a treatment for erectile dysfunction has achieved widospread acceptance due to low rates of drug induced priapism and priapism and penile fibrosis. We assessed the efficacy and side effects through
our
experinece in a pharmacologic erection program using prostaglandin E1 only. A total of 79 impotent patients received a prostaglandin E1 monotherapy as a first-line pharmacologica erection program for more than 2 monhths. Suspecting etiologies
were
non-vasculogenic in 39, vasculogenic in 38 and neurolgenic in 2 patients. The average duration using prostaglandin E1 was 4.6 months with a range of 2 to 14 months and the mean frequ3ency ofd drug use was 4.9 per week. The average prostaglandin
E1
dose
used by patients in the program was 7.4μg(0.37ml). No one had any side effects such as prolonged erection or fibrotic curdvdature. Dropout rate from prostagelandin E1 monotherapy after using for more than 2 months was 49%(39 patients0 and
reasons
were
penile pain in 7, drug expense in 4, inadeqate response in 3, recovery of spontaneous erection in 2 and unclear in 23 patients. Among these dropout patients, 14 received Trimix(the mixture of 15mg of dpapaverine, 1.25mg of phentolamine and 5μg
of
prostaglandin E1 iml of solution) injection as a secondline pharmacological erection program with a good erecdtile response. We conclude that the prostaglandin E1 monotherapy represents a safe and efficacious method for the first-line self
injection
therapy.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|